Astrazeneca Plc, the world's seventh-largest drug maker, expects sales in China to grow more than 20 percent annually from this year through 2010, outperforming China's market growth.
Given our portfolio, we believe AstraZeneca's growth in China should be faster than the country's drug market growth in the next two to three years as what we have achieved last year.
Last year, the UK-based pharmaceutical firm registered sales of US$320 million selling drugs like asthma medicine Symbicort, an increase of 19 percent from a year earlier.

28-03-2007 |  0 Hit(s) | (0 vote)

US moves to slap anti-dumping tariffs on China's rapidly-growing steel exports are likely to fail due to the strength of the US steel sector.
We don't see how the US producers can legitimately win anti-dumping cases. They have to demonstrate injury to domestic industry, but US steel firms have had record profits, Phelps told an industry conference in the southern city of Guangzhou.
He said that "political factors" were involved in the focus on China's booming steel exports to the US over the past few years.
The rule of thumb is two quarters of negative profits in the US to warrant market injury from imports.

28-03-2007 |  133 Hit(s) | (0 vote)

Inside the factory, engineers tinkered with machines that test how well tires hug slick roads while others trained customers on running additional gear.

02-02-2007 |  244 Hit(s) | (0 vote)

China's automobile export has reported a sustained, rapid growth in recent years. Relevant customs statistics show that the country exported nearly 300,000 complete vehicles from January to November 2006, up 88.8 percent over the same 2005 period. They included 85,000 sedans, a rise of 256 percent year-on-year, but their unit price dropped 19.5 percent year on year.

12-01-2007 |  1 Hit(s) | (0 vote)